Pdf the cloning of the epo gene in the early 1980s allowed for the development of recombinant. Approved september 18, 20 medical policy revisions erythropoietin stimulating agents esas updated the name of the policy. In these situations they decrease the need for blood transfusions. Epo is a protein hormone 165 amino acids primarily synthesized by the kidneys that contains 3 n glycan and 1 o glycan side chain. At, we keep tabs on over 200,000 clinical trials in the us and abroad, using medical data supplied directly by the us national institutes of health. Erythropoiesisstimulating agents esas are standard therapy for chronic kidney disease ckd patients with renal anemia. Who eml 20162017 erythropoietinstimulating agents december 2016. Name erythropoiesisstimulating agents accession number dbcat002721 description not available drugs. Therapeutic class overview erythropoiesisstimulating agents. Caution should be exercised when using esas with chemotherapeutic agents in diseases associated with. Evidencebased recommendations on erythropoiesisstimulating agents epoetin alfa eprex, epoetin beta neorecormon, epoetin theta, epoeitin zeta retacrit and darbepoetin alfa aranesp for treating anaemia in adults with cancer having chemotherapy the recommendations also apply to biosimilar products of the technologies that have a marketing authorisation allowing the use. It is produced by cloning the gene for erythropoietin. Fdas announcement applies to patients with earlystage kidney. These drugs are given by injection shot and work by.
Outcomes showed that use of esas significantly reduced the relative risk of red blood cell transfusions risk ratio rr 0. This and related erythropoiesisstimulating agents esas greatly benefited patients by decreasing debilitating symptoms, improving their quality of life, and freeing them from dependence on blood transfusions with their associated complications such as. In the case of anaemia caused by anticancer chemotherapy, research in the late 1990s and subsequently has suggested that the risks associated with such treatment include thromboembolic disease and promotion. Increasing incidence of anemia cases worldwide is driving the growth of. Benefits and harms of erythropoiesisstimulating agents for anemia related to cancer. Reimbursement policy erythropoiesis stimulating agents. Esa monitoring policy, effective october 1, 2006 pdf esa monitoring policy, effective april 1, 2006 pdf chapter 11 end stage renal disease esrd pdf chapter 8 outpatient esrd hospital, independent. Esas in the united states provides a classic example of how economics drive practice. Anemia is a common finding in cancer patients and can be a result of treatment or of underlying disease 1. Epoetin alfa epogen, procrit, epoetin alfa epbx retacrit are considered medically necessary.
Erythropoiesisstimulating agents are used to treat anemia and kidney disease. They are used to treat anemia due to end stage kidney disease, chemotherapy, major surgery, or certain treatments in hivaids. Pdf clinical pharmacokinetics and pharmacodynamics of. Although the introduction of erythropoiesisstimulating agents esas. The purpose of this medical policy is to provide a guide to coverage. This article was updated on june 20, 20, to reflect current web addresses. Nothing in this medical policy is intended to discourage or prohibit providing other medical advice or treatment. Erythropoiesisstimulating agents market global industry. Interpretation of blood tests and appropriate dose adjustments remains the responsibility of the renal unit. Thrombopoiesis stimulating agents prices and information.
Aranesp darbepoetin alfa epogen, procrit epoetin alfa mircera methoxy polyethylene glycolepoetin beta retacrit epoetin alfaepbx i. Drugs, such as epoetin alpha and darbepoetin alpha used to stimulate red cell production in anaemia. Chronic kidney disease ckd anemia treatment was revolutionized in the late 1980s with the introduction of recombinant human erythropoietin. Erythropoiesisstimulating agent esa nova scotia health authority. Median survival was significantly shorter with darbepoetin than with placebo. Erythropoiesisstimulating agents esa are medications which stimulate the bone marrow to. Local medicare contractors may continue to make reasonable and necessary determinations on all other uses of esas not specified in this ncd. Safety concerns of erythropoiesis stimulating agents esas. Chicagopatients with cancer are at risk for developing anemia.
Erythropoiesis stimulating agents injectable medication. Erythropoietin analogs contain the identical amino acid sequence as naturally occurring erythropoietin, and have the same biological effect. Dosing, uses, side effects, interactions, patient handouts, pricing and more from medscape reference. Esas are biologically engineered hormones produced by recombinant dna technology. The treatment of cancerassociated anemia remains a challenge, given that the most effective therapy for it erythropoiesisstimulating agents esas can also increase the risk for thromboembolic events. Pdf erythropoietin stimulating agents in the management. Therapeutic class overview erythropoiesisstimulating agents therapeutic class overviewsummary. Erythropoiesis stimulating agents and other growth factors. The maximum dosage of erythropoietin should not exceed a total of 60,000 units per week 5. Media in category erythropoiesis stimulating agents the following 3 files are in this category, out of 3 total. The dose frequency, depending on the patients condition, can vary from once in a week or once every two weeks. Traumatic brain injury continues to be the leading cause of death and disability in children and young adults.
Erythropoiesisstimulating agent administration and. June 24, 2011 the us food and drug administration fda today urged more conservative dosing guidelines for erythropoiesisstimulating agents. Treatment of anemia associated with chronic kidney disease if. Erythropoiesis stimulating agents esas boost the production of red blood cells and as such may play a role in optimising red cell mass pbm pillar 1 in specific groups of patients. Erythropoetin stimulating agents for the treatment for. Pdf erythropoiesisstimulating agents in renal medicine. Erythropoietin clinical trials, 944 results, page 1. A recombinant form of human erythropoietin used to increase differentiation of progenitor cells to red blood cells in the treatment of anemia. Recombinant erythropoietin is a manmade version of natural erythropoietin. When erythropoiesisstimulating agents esas are covered. Erythropoiesisstimulating agents should be discontinued after 6 to 8 weeks in nonresponders.
Recombinant human erythropoietin was first used clinically. An erythropoietin stimulating agent esa is an analog of erythropoietin. They work by increasing red blood cells in the blood. These drugs are given by injection shot and work by stimulating the production of more red blood cells. Treatment is indicated for patients at high risk for perioperative transfusions with significant, anticipated blood loss, for example, for patients expected to lose greater than two units of blood. The economic realities of erythropoiesisstimulating agent therapy in. Renal anemia is a wellrecognized complication of chronic kidney disease ckd, and the deficiency of erythropoietin. Erythropoiesisstimulating agents in the management of.
Effects of three kinds of erythropoiesisstimulating. Erythropoiesisstimulating agents prices and information. Esa monitoring policy, effective october 1, 2006 pdf. Erythropoietin production in patients with chronic renal. Epoetin alfa and darbepoetin alfa are erythropoiesis stimulating agents esas, approved for the treatment of anemia low red blood cells resulting from chronic kidney disease, chemotherapy. New dosing guidelines for erythropoiesisstimulating agents. The use of epoetin alfa, darbepoetin, or pegylated pegepoetin beta may be considered medically necessary for. Application for erythropoietinstimulating agents world health.
Thrombopoiesis stimulating agents are used to stop bleeding to treat chronic itp and hepatitis c. Aetna considers erythropoiesis stimulating agents experimental and investigational for all other indications, including the following conditions, because its use in these. Erythropoiesisstimulating agents in renal medicine article pdf available in the oncologist 16 suppl 3suppl 3. Who eml 20162017 application for erythropoietinstimulating agents erythropoietin type blood factors pdf. The original intent of our analysis was to evaluate risks for vte when cancer patients received esas vs placebocontrol. The erythropoiesis stimulating agents, epoetin alfa epogenprocrit, amgen and darbepoetin alfa aranesp, amgen can increase hemoglobin levels and subsequently reduce fatigue and the. However, few studies have compared the effects of different esas on anemia in identical predialysis ckd patients. Erythropoiesisstimulating agents esa are medications which stimulate the bone marrow to make red blood cells. Erythropoiesisstimulating agents in the treatment of. Erythropoiesis stimulating agents esas in cancer and related neoplastic conditions.
Erythropoiesis stimulating agents esas this article contains instructions for coding medical necessity in accordance with both the national coverage determination ncd and local coverage determination lcd and other cms instructions on darbepoetin alfa aranesp, dpa and epoetin alfa epogen, procrit, epo. Erythropoiesis stimulating agents esas boost the production of red blood cells and as. A phase iii, multicentre, openlabel, sequentialcohort, dose escalation study evaluated the efficacy and safety of romiplostim in thrombocytopenic patients with low or intermediate1risk mds. See the medicare benefit policy manual, chapter 11, section 90 and chapter 15, section 50. Recombinant erythropoietin drugs are known as erythropoietinstimulating agents esas. Erythropoiesis stimulating agents esas in cancer and. But, if the hemoglobin level approaches or goes over 11 gdl, the dose of the drug should be. Erythropoiesis stimulating agents injectable medication precertification request aetna precertification notification 503 sunport lane, orlando, fl 32809. All three erythropoiesisstimulating agents the two recombinant erythropoietins epogen and procrit and the. Safety concerns of erythropoiesis stimulating agents esas i. These agents are given as subcutaneous injections or as intravenous injections. Medical policy revisions erythropoietin stimulating agents. Seventynine patients who switched from epoetin beta to darbepoetin alfa group 1, and 82 patients who switched from darbepoetin alfa to epoetin beta pegol.
A largescale audit of blood transfusions in 2719 cancer patients showed that 38% had a hemoglobin level below 11. Erythropoiesis stimulating agents medical clinical. Erythropoietin stimulating agents in the management of anemia of chronic kidney disease article pdf available in patient preference and adherence 2. This medical policy is not intended to dictate to providers how to practice medicine.
This chart is created by aggregating the total number of claims for the drugs in this class divided by. A wide range of erythropoiesisstimulating agents to stimulate red blood cell production are currently in clinical use, but advances in our understanding of erythropoiesis have provided an ever. Erythropoiesis stimulating agents esas in cancer and related neoplastic conditions ncd 110. Key messages y esas are a method of optimising red cell mass pbm pillar 1 y esas are an authority item on the pharmaceutical benefits scheme pbs with a limited. Information on erythropoiesisstimulating agents esa. Erythropoiesisstimulating agents clinical criteria information included in this document erythropoiesisstimulating agents aranesp drugs requiring prior authorization. Cms has policies that effect the use of erythropoietin stimulating agents in esrd facilities. Erythropoiesis stimulating agents esa includes the following products. The safety of erythropoiesisstimulating agents for the. Erythropoiesis stimulating agents 2 high risk for perioperative transfusions with significant, anticipated blood loss, for example, for patients expected to lose greater than two units of blood. This policy addresses the following erythropoiesisstimulating agents esas. The administration of erythropoiesisstimulating agents. Erythropoetin stimulating agents for the treatment for renal anaemia information for primary care management of renal anaemia is coordinated by the anaemia nurse practitioner based at hull and east yorkshire hospitals nhs trust.
1235 608 984 451 475 188 965 461 1490 704 612 238 447 885 440 1021 486 1385 355 659 529 646 1047 99 1300 144 98 1375 1382